Waon therapy improves the prognosis of patients with chronic heart failure  by Kihara, Takashi et al.
Journal of Cardiology (2009) 53, 214—218
ORIGINAL ARTICLE
Waon therapy improves the prognosis of patients
with chronic heart failure
Takashi Kihara (MD)a, Masaaki Miyata (MD, FJCC)a, Tsuyoshi
Fukudome (MD)a, Yoshiyuki Ikeda (MD)a, Takuro Shinsato (MD)a,
Takuro Kubozono (MD)a, Shoji Fujita (MD)a, So Kuwahata (MD)a,
Shuichi Hamasaki (MD,FJCC)a, Hiroyuki Torii (MD)b,
Soki Lee (MD,FJCC)c, Hitoshi Toda (MD)c, Chuwa Tei (MD,FJCC)a,∗
a Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medicine,
Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan
b Department of Cardiology, Kagoshima City Medical Association Hospital, Kagoshima, Japan
c Department of Cardiology, Kagoshima City Hospital, Kagoshima, Japan
Received 21 October 2008; received in revised form 6 November 2008; accepted 7 November 2008
Available online 18 January 2009
KEYWORDS
Waon therapy;
Prognosis;
Heart failure
Summary
Background: We developed a Waon therapy (soothing warm therapy) and have pre-
viously reported that repeated Waon therapy improves hemodynamics, peripheral
vascular function, arrhythmias, and clinical symptoms in patients with chronic heart
failure (CHF). The aim of this study was to investigate the effect of Waon therapy
on the prognosis of CHF patients.
Patients and methods: We studied 129 patients with CHF in NYHA functional class III
or IV who were admitted to our hospital between January 1999 and March 2001. In
the Waon therapy group, 64 patients were treated with a far infrared-ray dry sauna
at 60 ◦C for 15min and then kept on bed rest with a blanket for 30min. The patients
were treated daily for 5 days during admission, and then at least twice a week after
discharge. In the control group, 65 patients, matched for age, gender, and NYHA
functional class, were treated with traditional CHF therapy. The follow-up time was
scheduled for 5 years.
Results: Recent, complete follow-up data on each patient were obtained. The overall
survival rate was 84.5% (Kaplan—Meier estimate). Twelve patients died in the control
group and 8 patients died in the Waon therapy group at 60 months of follow-up.
∗ Corresponding author. Tel.: +81 99 275 5316; fax: +81 99 275 5322.
E-mail address: tei@m.kufm.kagoshima-u.ac.jp (C. Tei).
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Cardiac events due to heart failure or cardiac death occurred in 68.7% of the control
group but only 31.3% of the Waon therapy group (P < 0.01) at 60 months of follow-up.
Conclusion: Waon therapy reduced cardiac events in patients with CHF. This therapy
is a promising non-pharmacological treatment for CHF.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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University. Informed consent was obtained from all
of the patients.© 2008 Japanese Colleg
reserved.
ntroduction
ecently, many researchers have reported that
asodilators, such as angiotensin-converting
nzyme inhibitors [1], angiotensin receptor block-
rs [2], and beta-blockers [3], improve prognosis
n patients with chronic heart failure (CHF).
urthermore, new technologies to treat CHF,
uch as cardiac rehabilitation, cardiac resynchro-
ization therapy, left ventricular assist devices,
nd left ventricular reconstruction surgery, have
een developed over the past decade. Despite
dvances in therapy for heart failure, improv-
ng clinical outcomes of patients with acute
eart failure remains a challenge for physicians.
e-hospitalization within 60—90 days occurs in
pproximately 30% of patients with acute heart
ailure [4].
We have developed a form of thermal therapy,
amely Waon therapy, which differs from the tradi-
ional sauna and is useful in the treatment of CHF.
aon therapy is deﬁned as ‘‘therapy in which the
ntire body is warmed in an evenly heated chamber
or 15min at a temperature that soothes the mind
nd body, and after the deep-body temperature has
ncreased by approximately 1.0—1.2 ◦C, the sooth-
ng warmth is sustained by maintaining the warmth
t rest for an additional 30min, with ﬂuids supplied
t the end to replace the loss from perspiration
5].’’ We have already reported that Waon therapy,
he repeated use of a dry sauna at 60 ◦C, improves
emodynamics [6], ameliorates symptoms [7], sup-
resses ventricular arrhythmias [8], and improves
ascular function [9] in CHF patients. Recently, in
prospective multicenter case—control study, we
ound that 2 weeks of Waon therapy improved clin-
cal symptoms and cardiac function in CHF patients
10].
Furthermore, we reported that repeated Waon
herapy improves survival in TO-2 cardiomyopathic
amsters with heart failure [11]. However, the
ffect of Waon therapy on prognosis in CHF
atients has not yet been elucidated. Thus, the
urpose of this study was to investigate the
ffect of Waon therapy on the prognosis of CHF
atients.
W
W
wethods
atients and study design
he study subjects included 129 CHF patients who
ere admitted to Kagoshima University Hospital,
agoshima City Hospital, or Kagoshima City Medi-
al Association Hospital between January 1999 and
arch 2001. All patients received traditional med-
cations for CHF, such as angiotensin-converting
nzyme inhibitors or angiotensin receptor block-
rs, beta-blockers, diuretics, and digitalis. None
f these patients was implanted with a deﬁbrilla-
or device. Sixty-four patients were treated daily
ith Waon therapy for 5 days after admission, and
aon therapy was continued at least twice a week
n an out-patient clinic after hospital discharge. The
emaining 65 control patients, who were matched
ith the Waon therapy group for age, gender, and
tiology and severity of CHF, continued medical
herapy for CHF.
Clinical characteristics at discharge from the
rst admission were considered as the patient’s
aseline characteristics. Data on body mass index,
eart rate, systolic blood pressure, and diastolic
lood pressure were also measured at discharge
rom the ﬁrst hospitalization. The baseline data
lso included the more recent data on the cardio-
horacic ratio (CTR) measured by chest radiography
nd left ventricular diastolic dimension and left
entricular ejection fraction measured by two-
imensional echocardiography during the ﬁrst
dmission.
All 129 patients were followed-up for 5 years,
nd cardiac events, such as cardiac death and re-
ospitalization due to heart failure, were compared
etween the control and Waon therapy groups.
The study protocol was approved by the Ethics
ommittee of the Faculty of Medicine, Kagoshimaaon therapy
aon therapy uses a far infrared-ray dry sauna,
hich is evenly maintained at 60 ◦C and differs
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Table 1 Baseline clinical characteristics.
Waon therapy group Control group
P-value
(n = 64) (n = 65)
Age (years) 61.9± 12.1 64.6± 9.2 ns
Gender (M/F) 40/24 42/23 ns
DCM/ICM/Other disease 39/16/9 45/13/7 ns
NYHA functional class (average) 2.6± 0.6 2.6± 0.5 ns
Body mass index (kg/m2) 22.6± 3.0 21.9± 3.5 ns
Heart rate (beats/min) 74± 13 71± 9 ns
Systolic BP (mmHg) 112± 15 111± 17 ns
Diastolic BP (mmHg) 77± 69 70± 10 ns
CTR (%) 56.2± 5.7 54.8± 5.9 ns
LVDd (mm) 58.9± 11.7 59.0± 7.8 ns
LVEF (%) 38.5± 15.2 35.8± 10.9 ns
AF (%) 32.8 36.9 ns
Medications
ACE-I or ARB (%) 68.8 64.6 ns
Beta-blocker (%) 60.9 56.9 ns
Digitalis (%) 39.1 49.2 ns
Diuretics (%) 73.4 83.1 ns
Statin (%) 18.8 13.8 ns
NYHA
F, le
eptor
S
D
a
b
sDCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy;
thoracic ratio; LVDd, left ventricular diastolic dimension; LVE
angiotensin-converting enzyme inhibitor; ARB, angiotensin rec
from traditional sauna. Waon therapy has no hydra-
tion pressure and was performed as previously
reported [6]. Brieﬂy, the patients were placed in a
supine or sitting position in a sauna system evenly
maintained at 60 ◦C for 15min, and then, they
underwent bed rest with a blanket to keep them
warm for an additional 30min. All patients were
weighed before and after the therapy, and oral
hydration with water was used to compensate for
weight lost due to perspiration.
p
c
f
K
Figure 1 Re-hospitalization due to heart failure or cardiac
31.3% in the Waon therapy group (P < 0.01) at 60 months of fo, New York Heart Association; BP, blood pressure; CTR, cardio-
ft ventricular ejection fraction; AF, atrial ﬁbrillation; ACE-I,
blocker; ns, not signiﬁcant.
tatistical analyses
ata were analyzed using Stat View 4.0. All data
re expressed as the mean± SD. Differences in
aseline characteristics were evaluated by the chi-
quare test or unpaired t-test. The cardiac event
oint was the time-to-the-ﬁrst-event of combined
ardiac death or re-hospitalization due to heart
ailure. Cardiac event curves were analyzed with
aplan—Meier method, and the log-rank test was
death rate was 68.7% in the control group compared to
llow-up.
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oaon therapy improves the prognosis of patients w
sed to assess the differences between two groups.
value of P < 0.05 was considered statistically
igniﬁcant.
esults
aseline patient characteristics
aseline clinical characteristics in the control and
aon therapy groups are shown in Table 1. There
ere no signiﬁcant differences in age, gender,
r etiology and severity of CHF between the
wo groups. In addition, there were no signiﬁ-
ant differences in the use of CHF medications,
uch as angiotensin-converting enzyme inhibitors,
ngiotensin receptor blockers, beta-blockers, dig-
talis, diuretics, or statins between the two
roups.
ardiac events
ll 129 patients were followed-up for 5 years;
here was no death due to non-cardiac events dur-
ng this study, and the overall survival rate was
4.5%. Twelve patients died in the control group
nd 8 patients died in the Waon therapy group over
0 months of follow-up. Re-hospitalization due to
orsening CHF occurred in 44 patients in the con-
rol group and 20 patients in the Waon therapy
roup.
The cardiac event rate, such as cardiac death or
e-hospitalization due to heart failure was 68.7% in
he control group and 31.3% in the Waon therapy
roup (P < 0.01) at 60 months of follow-up.
Kaplan—Meier analysis demonstrated that Waon
herapy signiﬁcantly reduced the cardiac event rate
ompared with the control group, and the reduction
f cardiac events by Waon therapy was 38% at 60
onths of follow-up (Fig. 1).
iscussion
his retrospective follow-up study demonstrated
hat Waon therapy decreased cardiac death and
e-hospitalization in patients with CHF over a 60-
onth follow-up period. Although we have already
eported in an animal study that repeated Waon
herapy improved survival in TO-2 cardiac hamsters
ith CHF [11], this is the ﬁrst report to show the
eneﬁcial effect of Waon therapy on the long-term
rognosis of CHF patients.
We have already reported that Waon therapy
nduced thermal vasodilation of the systemic and
w
c
h
i
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ulmonary arteries and veins, reduced cardiac pre-
oad and after-load, and improved hemodynamics
nd clinical symptoms in CHF patients [6]. In addi-
ion, we have reported that 4 weeks of Waon
herapy signiﬁcantly improved clinical symptoms,
ncreased ejection fraction, and decreased cardiac
ize on echocardiography and chest radiography in
HF patients [7]. Recently, we conﬁrmed the ben-
ﬁcial effects and safety of Waon therapy applied
or 2 weeks in CHF patients in a prospective multi-
enter case—control study [10].
We previously demonstrated that Waon ther-
py improved not only cardiac function, but also
ndothelial function in patients with CHF. We have
eported that 2 weeks of Waon therapy signif-
cantly reduced brain natriuretic peptide blood
evels and improved ﬂow-mediated vasodilation in
HF patients [9]. Furthermore, we have reported
hat Waon therapy for 2 weeks decreased ventric-
lar premature contractions and increased heart
ate variability in CHF patients [8], suggesting
hat Waon therapy decreased sympathetic nervous
ctivity and improved ventricular arrhythmias.
In addition, Waon therapy improved vascular
unction in patients with coronary risk factors
12,13] or peripheral arterial disease [14,15] and
mproved exercise capacity in patients with chronic
bstructive pulmonary disease [16].
Waon therapy improves cardiac and vascular
unction and reduces ventricular arrhythmias in
HF patients. We think that these beneﬁcial effects
f Waon therapy led to the reduction of cardiac
vents in CHF patients in the present study.
Furthermore, we reported that Waon therapy
ncreased mRNA and protein expression of endothe-
ial nitric oxide synthase (eNOS) and production of
itric oxide (NO) in Syrian golden hamsters [17]
nd TO-2 cardiomyopathic hamsters [18]. This up-
egulation of eNOS and NO may play an important
ole in the beneﬁcial effects of Waon therapy in CHF
atients.
tudy limitation
his study was a retrospective study to investi-
ate the effect of Waon therapy on the prognosis
n patients with CHF. A further prospective ran-
omized multicenter study is needed to clarify the
eneﬁcial effect of Waon therapy on the prognosis
f CHF patients.
In addition, patients in the Waon therapy groupent to the hospital at least twice per week. In
ontrast, patients in the control group went to the
ospital once per month. Therefore, this difference
n frequency of hospital visits may affect the result
f this study.
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Conclusion
In this retrospective follow-up study, we demon-
strated that Waon therapy reduced cardiac events
due to heart failure over a 60-month follow-up
period. Therefore, this therapy is a promising non-
pharmacological treatment for CHF.
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